Clinical Trial Update: Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) [Phase 2]

View source ↗

Summary

A multicenter Phase II study evaluated the activity and safety of everolimus in patients with marginal zone B-cell lymphoma (MZL) and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone B-cell Lymphoma

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Conditions: Marginal Zone B-cell Lymphoma | Phase 2 | Status: COMPLETED